04852nam 2200721Ia 450 991109808960332120251117082159.09786612440861978128244086912824408619781848162570184816257X(CKB)2550000000003540(EBL)477135(OCoLC)647850790(SSID)ssj0000338410(PQKBManifestationID)11284920(PQKBTitleCode)TC0000338410(PQKBWorkID)10295802(PQKB)10082258(MiAaPQ)EBC477135(WSP)00000710 (Au-PeEL)EBL477135(CaPaEBR)ebr10361671(CaONFJC)MIL244086(Perlego)848487(EXLCZ)99255000000000354020080718d2009 uy 0engurcuu|||uu|||txtccrHandbook of cardiac stem cell therapy /edited by Ioannis Dimarakis ... [et al.]1st ed.London Imperial College Pressc20091 online resource (306 p.)Description based upon print version of record.9781848162563 1848162561 Includes bibliographical references and index.3. Embryonic Stem Cells and Their Therapeutic Potential Tomo Šari ́c, Shuhua Chen, Naidu Kamisseti, Marcel Halbach, Michael Xavier Doss, Johannes Winkler, Jürgen Hescheler and Agapios Sachinidis Embryonic Stem Cells; ES Cell-Derived Cardiomyocytes; Generation of cardiomyocytes from ES cells; Functional characteristics of ES cell-derived cardiomyocytes; Animal models of cardiomyocytes derived from ES cells; Other Animal Models for ES Cell-Based Therapeutics; Models for neural diseases; Models for therapy for type I diabetes mellitus; Animal models for liver and kidney regenerationCell replacement therapy for other organ systems Barriers to Successful Use of ES Cell-Based Therapies; Ethical concerns; Safety concerns and purity; Rejection of allogeneic cells; Conclusions; References; 4. Umbilical Cord Blood Cells for Cardiac Repair Elad Maor, Arnon Nagler and Jonathan Leor; Introduction; Myocardial Infarction and Heart Failure; Myocardial Regeneration and Cell-Based Therapy; Problems with the Available Cell Sources; The Rationale for Using UCB Progenitor Cells for Myocardial Repair; Data from Animal Models; How Do Cord Blood Cells Repair Ischemic Tissue?Ex vivo Expansion Immunosuppression and Graft versus Host Disease; Summary; References; 5. Amniotic Stem Cells Paolo De Coppi, Anthony Atala and Saverio Sartore; Introduction; Amniocentesis; Differentiated Cells from Amniotic Fluid; Mesenchymal Stem Cells from Amniotic Fluid; Amniotic Fluid Stem Cells; Cell preparation and culture methods; Cell cloning; Telomerase activity; Differentiation potential induction of osteogenic phenotype; Induction of adipogenic lineage; Induction of myogenic phenotype; Induction of endothelial phenotype; Induction of hepatocytes phenotypeInduction of neurogenic phenotype Clonal and proliferative analyses; Conclusion; References; 6. Stem Cell Homing to Injury in Cellular Cardiomyoplasty Adil Al Kindi, Dominique Shum-Tim and Ray Chu-Jeng Chiu; Introduction; The Prelude: Insights from Bone Marrow Transplantation; Animal Studies; The Signaling Molecules; Summary and Conclusions; References; 7. A Molecular Imaging Perspective on Cardiac Repair with Stem Cells Kishore Bhakoo; Introduction; Radionuclide Imaging; Optical Imaging; Ultrasound; MRI Imaging; Intracellular MRI Contrast Agents; MRI Tracking of Stem Cells in the HeartMultimodalityThis book is an impressive compilation of contributions on the hot topic of cardiac stem cell therapy from leading groups all over the world. In the assembly of chapters, a structured approach is adopted; starting from the clinician's perspective, all developments in both the experimental and clinical research areas are covered. This journey will take the reader from the bench-top to the bedside, with all chapters written by leading authorities in their respective fields, including data still in press with medical journals.HeartDiseasesTreatmentStem cellsTransplantationStem cellsHeartDiseasesTreatment.Stem cellsTransplantation.Stem cells.616.1206616/.02774Dimarakis Ioannis1939970MiAaPQMiAaPQMiAaPQBOOK9911098089603321Handbook of cardiac stem cell therapy4692716UNINA04240nam 2200781Ia 450 991109024550332120251117115608.09786612358241978128235824912823582439780520939288052093928X9781597344500159734450810.1525/9780520939288(CKB)111090529079620(EBL)224570(OCoLC)808037855(SSID)ssj0000092615(PQKBManifestationID)11114332(PQKBTitleCode)TC0000092615(PQKBWorkID)10023398(PQKB)10348720(DE-B1597)518878(OCoLC)55538532(DE-B1597)9780520939288(Au-PeEL)EBL224570(CaPaEBR)ebr10057097(CaONFJC)MIL235824(Perlego)550830(MiAaPQ)EBC224570(EXLCZ)9911109052907962020031010d2004 uy 0engurnn#---|u||utxtrdacontentcrdamediacrrdacarrierThe $800 million pill the truth behind the cost of new drugs /Merrill Goozner1st ed.Berkeley University of California Press20041 online resource (304 pages)Description based upon print version of record.9780520246706 0520246705 9780520239456 0520239458 Includes bibliographical references and index.Front matter --Contents --Introduction --PART ONE. BIOHYPE --PART TWO. DIRECTED RESEARCH --PART THREE. BIG PHARMA --Notes --Bibliography --Acknowledgments --IndexWhy do life-saving prescription drugs cost so much? Drug companies insist that prices reflect the millions they invest in research and development. In this gripping exposé, Merrill Goozner contends that American taxpayers are in fact footing the bill twice: once by supporting government-funded research and again by paying astronomically high prices for prescription drugs. Goozner demonstrates that almost all the important new drugs of the past quarter-century actually originated from research at taxpayer-funded universities and at the National Institutes of Health. He reports that once the innovative work is over, the pharmaceutical industry often steps in to reap the profit. Goozner shows how drug innovation is driven by dedicated scientists intent on finding cures for diseases, not by pharmaceutical firms whose bottom line often takes precedence over the advance of medicine. A university biochemist who spent twenty years searching for a single blood protein that later became the best-selling biotech drug in the world, a government employee who discovered the causes for dozens of crippling genetic disorders, and the Department of Energy-funded research that made the Human Genome Project possible--these engrossing accounts illustrate how medical breakthroughs actually take place. The00 Million Pill suggests ways that the government's role in testing new medicines could be expanded to eliminate the private sector waste driving up the cost of existing drugs. Pharmaceutical firms should be compelled to refocus their human and financial resources on true medical innovation, Goozner insists. This book is essential reading for everyone concerned about the politically charged topics of drug pricing, Medicare coverage, national health care, and the role of pharmaceutical companies in developing countries.Eight hundred million dollar pillPrescription pricingDrugsPricesPharmaceutical industryConsumer educationPrescription pricing.DrugsPrices.Pharmaceutical industry.Consumer education.338.4/3/61510973Goozner Merrill1950-1991119MiAaPQMiAaPQMiAaPQBOOK9911090245503321The4768453UNINA